| INTRODUCTION
Obstructive sleep apnea (OSA) is characterized by the occurrence of daytime sleepiness, loud snoring, witnessed breathing interruptions or awakenings due to gasping or choking in the presence of at least five obstructive respiratory events (apneas, hypopneas, or respiratory related arousals) per hour of sleep collapse. 1 The presence of 15 or more obstructive respiratory events per hour of sleep in the absence sleep related symptoms is also sufficient for the diagnosis of OSA. OSA is known to be associated with cardiovascular morbidity and mortality. 2 OSA increases the risk of cardiovascular diseases (CVD) including hypertension, heart failure, arrhythmias, and coronary artery diseases. 3 The pathogenesis is likely to be multifactorial process, including sympathetic nervous system excitation, vascular endothelial dysfunction, oxidative stress and inflammation. 4 Recurrent pharyngeal collapse during sleep can lead to repetitive sequences of hypoxia-reoxygenation, which induce activation of the proinflammatory factors IL-6, C-reactive protein (CRP) and TNF-α. 5 Inflammation is one of the fundamental factors contributing to the onset and progression of atherosclerosis. 6 Significant roles of leukocytes in atherothrombosis are already known. 7 Recently, neutrophil-to-lymphocyte ratios (NLR) and platelet-to-lymphocyte ratios (PLR) have emerged as potential new biomarkers that indicate the presence of inflammation.
And also, they can single out individuals at risk for future cardiovascular events. 8, 9 Low level systemic inflammation and hypercoagulability have been associated with OSA and coranary artery disease (CAD). 10 Platelets exhibit a crucial linkage between thrombosis, inflammation, and atherogenesis by assembling to sites of vascular damage and inflammation. Mean platelet volume (MPV) has been shown to be indicator of platelet activation. 11 And also, red blood cell distribution width (RDW)
which is a numerical measure of the size variability of circulating erythrocytes, increases platelet activation. It was shown to be a strong independent predictor of morbidity and mortality in patients with chronic heart failure and in patients with coronary artery disease.
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Several studies have examined the relationship between PLR and RDW, NLR and RDW, MPV and RDW separately in OSA patients.
However, the comparison between all of these parameters have not been determined in the same patient group to date. In this study, we analyzed the association of PLR, NLR, MPV, and RDW all together with the severity of the disease and the presence of cardiovascular diseases in patients with OSA. The RDW, MPV, platelet, neutrophil, and lymphocyte counts were determined using the Abbott Cell-Dyne 3700 Hematology Analyzer, as one part of a hemogram. The NLR and PLR were obtained from the absolute neutrophil and platelet counts, respectively, divided by the absolute lymphocyte counts.
| MATERIALS AND METHODS

| Statistical analysis
All results were expressed as the mean±standard deviation. All analyses were done using the Statistical Package for the Social Sciences (SPSS), V. 15.0 (SPSS, Chiacago, IL, USA). A power analysis was conducted to determine the number of participants needed in the study.
The α for the ANOVA will be set at <.012. 
| RESULTS
The clinical characteristics and laboratory parameters of the study population are summarized in Only RDW differed significantly among the four groups (P=.04).
RDW showed a significant increase in parallel with the severity of OSAS.
The polsomnographic study results are presented in Table 2 . The distribution of sleep stages, AHI, mean and minimum oxygen saturation, ODI were significantly different among the groups (P<.01). All the patients had ESS score <10 and there was no significant difference among the groups with respect to ESS (P=.028).
We also noted the correlations between polysomnographic results and laboratory parameters. Spearman correlation analysis showed a significant correlation only between RDW and polysomnographic parameters. The MPV, NLR and PLR were not significantly correlated with the polysomnographic parameters. RDW was positively correlated with the AHI and ODI but negatively correlated with the mean oxygen saturation (P<.05; Table 3 ).
There were no significant differences in the platelet, lymphocyte, neutrophil counts; NLR; PLR; MPV and RDW between patients with OSA with vs without CVD (P>.05). RDW values were significantly higher in patients with than without CVD risk factors (P=.02). Figure 1 ).
T A B L E 1 Demographic and laboratory findings of the study group
| DISCUSSION
Ostructive sleep apnea has been associated with many comorbidities such as cardiovascular diseases, pulmonary diseases, endocrine dysfunctions and neuropsychiatric problems. Although the exact mechanism underlying these problems remains unclear, chronic inflammation has been implicated in their pathogenesis. 15 To address this issue, we analyzed several inflammatory factors such as PLR, NLR, MPV, and RDW levels in patients with OSA. And also we evaluated the association of these markers with the severity of the disease and the presence of cardiovascular diseases in patients with OSA. Detection of inflammatory factors in OSA patients may help us to predict the risk and severity of these comorbid diseases.
Neutrophil-lymphocyte ratio is a new biomarker which indicates
the presence of inflammation. Evaluation of the NLR in the diseases may help us to predict the progression and prognosis of the disease processes. Various studies have demonstrated the correlation between the NLR and lung cancer, pneumonia and tuberculosis.
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Gunay and associates indicated that NLR was higher in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) than in patients with stable COPD and healthy controls. 19 However, in our study there was no significant difference among the OSA groups with respect to NLR. And also, NLR was not significantly correlated with polysomnographic parameters. This result is in agreement with
Korkmaz and associates, who found no difference in NLR between patients with and without OSA.
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Platelet-lymphocyte ratio, another recent novel biomarker, has been proved to be both sensitive and reliable for evaluation of inflammation. Sunbul and associates found that increased PLR was associated with non-dipper state in hypertensive patients. 21 Koseoglu and associates reported that PLR is strongly associated with the severity of OSA and CVD in patients with OSA. 8 However, in our study, PLR was similar between the OSA and control groups.
There was no significant difference in the PLR in patients with OSA with vs without CVD.
Chronic inflammation, hypoxia, and sympathetic overactivity are associated with the pathogenesis of platelet activation in OSA. 5 MPV is another marker of platelet activation. 22 Recent reports have demonstrated that MPV is significantly higher in patients with than without OSA. 8, 23 The increased cardiovascular risk in patients with OSA may also be linked to abnormalities of coagulation and excessive platelet activation. 24 In our study, we did not find any significant correlation between MPV and the severity of OSA. Our result is in agreement with that of Kurt and associates, who reported that the severity of OSA was not correlated with MPV.
4
Inflammation has also the capacity to shorten red blood cell survival. 25 Inflammation has been proposed as a key point in the association of RDW with the cardiovascular and pulmonary diseases.
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Ozsu and associates have demonstrated that OSA patients have elevated levels of RDW compared to controls but they did not find any association between the severity of OSA and RDW. 27 However, in our study, RDW differed significantly among the OSA groups.
Moreover, there was a significant correlation between the level of RDW and the severity of OSA. A high level of RDW in OSA may be caused by numerous factors including inflammation, age, and obesity. In addition, in our study, there was a positive correlation between the severity of OSA and age and BMI. And also, we found a significant positive correlation between the level of RDW and AHI and ODI. All these results suggest that RDW may play a role in the pathogenesis of OSA.
An elevated RDW may be an indicator of underlying inflammation in OSA. RDW can demonstrate the reverse consequences of OSA-associated comorbidities, because vascular damage due to systemic inflammation is an important underlying mechanism in these diseases. Hypoxemia, inflammation, increased heart rate, and blood pressure in OSA lead to cardiovascular morbidity. 28 We found that RDW values were significantly higher in patients with than without CVD risk factors. An elevated RDW may also be proposed as a simple and diagnostic tool for monitoring patients with OSA, those especially with cardiovascular disease. To address this issue, we determined the cut-off value of RDW (>16) to demonstrate the presence of CVD risk factors.
Taken together, our results indicate that among these laboratory parameters, only RDW can be used as an inexpensive tool for triaging OSA patients for polysomnographic evaluation in sleep laboratories and these patients could able to reach earlier treatment options.
And also, RDW might also be used as a marker of the response and patient compliance with continuous positive airway pressure treatment. However, there are some limitations of our study that have to be mentioned. We did not follow the patients prospectively and did not investigate the effect of continuous positive airway pressure treatment on RDW. In this context, prospective, randomized, controlled studies before and after continuous positive airway pressure treatment are needed to assess the association between these parameters and OSA.
